Hemab Therapeutics Holdings, Inc. (COAG)
41.45
+1.03
(+2.55%)
USD |
NASDAQ |
Oct 30, 16:00
41.45
0.00 (0.00%)
After-Hours: 20:00
Hemab Therapeutics Holdings Net Income (Quarterly) : -24.15M for June 30, 2026
Net Income (Quarterly) Chart
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -24.15M |
| March 31, 2026 | -22.69M |
| Date | Value |
|---|---|
| June 30, 2025 | -12.21M |
| March 31, 2025 | -15.31M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Arrowhead Pharmaceuticals, Inc. | -178.92M |
| Oncolytics Biotech, Inc. | -9.442M |
| Sangamo Therapeutics, Inc. | -31.00M |
| Sarepta Therapeutics, Inc. | -4.89M |
| Anixa Biosciences, Inc. | -2.625M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 24.15M |
| EPS Diluted (Quarterly) | -0.5171 |
| Enterprise Value | 1.480B |
| Earnings Yield | -3.84% |
| Normalized Earnings Yield | -3.840 |